Return to List
Results 1–6 of 6
Title Date
1.

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT: Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years. There is no consensus on criteria to identify primary ovaria...

July 2014

PDF Format
2.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT: In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatme...

June 2014

PDF Format
3.

Evaluation of Uncomplicated Stress Urinary Incontinence in Women Before Surgical Treatment

Number 603

ABSTRACT: Stress urinary incontinence (SUI) is a condition of involuntary loss of urine on effort, physical exertion, sneezing, or coughing that is often bothersome to the patient and frequently affe...

June 2014

PDF Format
4.

Depot Medroxyprogesterone Acetate and Bone Effects

Number 602

(Replaces Committee Opinion Number 415, September 2008)

ABSTRACT: Depot medroxyprogesterone acetate (DMPA) is a highly effective injectable contraceptive that affords privacy and has a convenient dose schedule of four times per year, making it appealing t...

June 2014

PDF Format
5.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuva...

June 2014

PDF Format
6.

Ethical Issues in the Care of the Obese Woman

Number 600

ABSTRACT: Rates of obesity in the United States have increased rapidly over the past several decades, and physicians should be prepared to care for obese patients in a nonjudgmental manner, being cog...

June 2014

PDF Format